PD-L2 Fc Chimera, Human
| Synonyms | B7-DC; bA574F11.2; Btdc; Butyrophilin B7-DC; Butyrophilin-like Protein; CD273 antigen; CD273; CD273PD-1 ligand 2; MGC142240; PD-1-ligand 2; PDCD1L2MGC142238; PDCD1LG2; PDL2; PD-L2 |
| Description | PD-L1 and PD-L2 are ligands for PD-1, a costimulatory molecule that plays an inhibitory role in regulating T cell activation in the periphery. PD-L2 also known as PD-L2, B7-DC serves as a negative and a positive regulator of T cell function. The expression and function of PD-L2 are similar to PD-L1. Both PD-L2−PD-1 and PD-L1−PD-1 signals inhibit T cell proliferation by blocking cell cycle progression but not by increasing cell death. PD-L2−PD-1 interactions are able to inhibit TCR-mediated proliferation and cytokine production in the absence of CD28 costimulation. Threshold for T cell activation may be a balance between activating signals, such as those delivered by the engagement of CD28 by B7-1 and B7-2, and inhibitory signals, mediated by engagement of PD-1 by PD-L1 and PD-L2. The structural conservation of B7-like and CD28-like receptors may reflect the distance between T cells and APCs in the immunological synapse. The PD-L−PD-1 pathway may play a key role in the induction and/or maintenance of peripheral tolerance and autoimmune disease. Because PD-L1 and PD-L2 can inhibit effector T cell proliferation and cytokine production, the PD-L−PD-1 pathway may be an attractive therapeutic target. Blocking the PD-1 pathway may enhance anti-tumor immunity, whereas stimulating this pathway may be useful for down-regulating ongoing immune responses in transplant rejection and autoimmune and allergic diseases. Recombinant Human PD-L2 Fc Chimera produced in HEK293 cells is a polypeptide chain containing 432 amino acids with the C-termimal human IgG1 Fc fragment. A fully biologically active molecule, rhPD-L2 has a molecular mass of 75 kDa analyzed by reducing SDS-PAGE and is obtained by chromatographic techniques at GenScript. |
| Accession No | Q9BQ51 |
| Species | Human |
| Source | HEK293 |
| Biological Activity | Immobilized PD-L2 Fc Chimera, Human (Z03417) at 5 μg/mL (100 μL/well) can bind Biotin-PD-1 Fc, Human with a linear range of 2.44-39.06 ng/mL when detected by Streptavidin-HRP. |
| Sequence | LFTVTVPK ELYIIEHG SNVTLECN FDTGSHVN LGAITASL QKVENDTS PHRERATL LEEQLPLG KASFHIPQ VQVRDEGQ YQCIIIYG VAWDYKYL TLKVKASY RKINTHIL KVPETDEV ELTCQATG YPLAEVSW PNVSVPAN TSHSRTPE GLYQVTSV LRLKPPPG RNFSCVFW NTHVRELT LASIDLQS QMEPRTHP |
| Measured Molecular Weight | 75 kDa, observed by reducing SDS-PAGE |
| Purity | > 97% as analyzed by reducing SDS-PAGE |
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS, 5% trehalose and mannitol. |
| Reconstitution | Reconstituted in ddH2O or PBS at 100 μg/ml |
| Endotoxin Level | < 0.2 EU/μg, determined by LAL method. |
| Storage | Lyophilized recombinant PD-L2 Fc Chimera, Human remains stable up to 6 months at lower than -70°C from date of receipt. Upon reconstitution, Human PD-L2 Fc Chimera should be stable up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
| Note | For research use only |
Immobilized PD-L2 Fc Chimera, Human at 5 μg/mL (100 μL/well) can bind Biotin-PD-1 Fc, Human with a linear range of 2.44-39.06 ng/mL.
For more documents, please visit "Technical Support".
| Cat. No. Z03417 | ||
|---|---|---|
Size |
Price |
|
| 100 μg | $250.00 | |
| 1 mg | $1200.00 | |
